Antibody-mediated Rejection Clinical Trial
Official title:
Elimination of Cardiac and Inflammatory Biomarkers and Adipokines by Therapeutic Plasma Exchange
Therapeutic plasma exchange (TPE) is an established treatment modality for the acute removal of pathophysiological relevant mediators in various diseases. Adipokines have recently been found to play an important role in a variety of immunologic diseases. However, in many of these disease states cardiac and inflammatory involvement is common and biomarkers are routinely used for diagnosis or assessment of therapeutic success. The effect of TPE on biomarkers used in the clinical routine has not been investigated. The aim of this study is to determine adipokine and cardiac biomarker removal during TPE therapy.
We performed a observational prospective single-centered study. Every patient received two consecutive therapeutic plasma exchange (TPE) sessions during the study. Plasma exchange therapy was performed using either the Spectra Optia® or the Octo Nova® apheresis system. Anticoagulation was applied either by heparin or citrate. The prescribed dose of exchange volume of every TPE treatment was 1.1-times the individual calculated total plasma volume, using the Nadler-Allen equation. A substitute fluid with 5% albumin concentration was used in every treatment. Blood samples for measurement of different adipokines (resistin, leptin, soluble ICAM-1, soluble CD40 ligand, monocyte chemoattractant protein-1 (MCP-1), soluble tumor necrosis factor receptor (sTNF-R) as well as cardiac and inflammatory biomarkers and routine chemistry were drawn before (pre-TPE) and at the end (post-TPE) of the first and second TPE session. ;
Observational Model: Cohort, Time Perspective: Prospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04367610 -
Effects of A Standardized Treatment Approach on Kidney Transplant Recipients With Antibody-Mediated Rejection
|
||
| Completed |
NCT05021484 -
Felzartamab in Late Antibody-Mediated Rejection
|
Phase 2 | |
| Terminated |
NCT02120482 -
Combined Apheresis for ABO-incompatible Transplantation - a Pilot Study
|
N/A | |
| Terminated |
NCT03744910 -
Clazakizumab for the Treatment of Chronic Active Antibody Mediated Rejection in Kidney Transplant Recipients
|
Phase 3 | |
| Terminated |
NCT03221842 -
Efficacy and Safety of Human Plasma-derived C1-esterase Inhibitor as add-on to Standard of Care for the Treatment of Refractory Antibody Mediated Rejection (AMR) in Adult Renal Transplant Recipients
|
Phase 3 | |
| Terminated |
NCT01895127 -
Efficacy and Safety of Eculizumab for Treatment of Antibody-mediated Rejection Following Renal Transplantation
|
Phase 2 | |
| Completed |
NCT02013037 -
The De-novo Use of Eculizumab in Presensitized Patients Receiving Cardiac Transplantation
|
Phase 3 | |
| Recruiting |
NCT03737136 -
Comparison Between Bortezomib and Rituximab Plus Plasmapheresis in AMR
|
N/A | |
| Recruiting |
NCT05913596 -
The Safety and Efficacy of CD38 Monoclonal Antibody Monotherapy for CaAMR in Renal Transplantation
|
N/A | |
| Active, not recruiting |
NCT04541914 -
Diagnostic Efficacy of Molecular Diagnostic Method for AMR in ABOiKT
|
N/A | |
| Withdrawn |
NCT03805178 -
Lung Transplant Plasmapheresis/Belatacept/Carfilzomib for Antibody Mediated Rejection and Desensitization
|
Phase 2 | |
| Recruiting |
NCT06112951 -
A Prospective Randomized Trial of ECP in Subclinical AMR
|
N/A | |
| Active, not recruiting |
NCT04897438 -
Donor-derived Cell-free DNA for Early Diagnosis of Antibody-mediated Rejection
|
N/A | |
| Recruiting |
NCT05004493 -
Biorepository and Registry for Plasma Exchange Patients
|
||
| Completed |
NCT04026087 -
Subclass of Donor-specific Antibody as a Risk Factor of Antibody Mediated Rejection in Renal Transplantation
|
||
| Active, not recruiting |
NCT03994783 -
Transplant Antibody-Mediated Rejection: Guiding Effective Treatments
|
Phase 3 | |
| Not yet recruiting |
NCT05862766 -
Isatuximab in Lung Transplant Recipients
|
Early Phase 1 | |
| Recruiting |
NCT04368962 -
DSA Risk Factors in MMF-based Immunosuppressed Post-transplanted Patients
|
||
| Completed |
NCT03444103 -
A Pilot Trial of Clazakizumab in Late ABMR
|
Phase 2 | |
| Recruiting |
NCT05140018 -
Incidence, Course and Outcome of ABMR in Kidney Transplantation
|